Research programme: coronavirus vaccines - Soligenix/University of Hawaii
Alternative Names: CiVax™; CiVax™ vaccine - Soligenix; COVID-19 Vaccine Programme - Soligenix; COVID-2019 vaccine - Soligenix; SARS-CoV-2 virus vaccine - SoligenixLatest Information Update: 27 Nov 2024
At a glance
- Originator Soligenix; University of Hawaii
- Class Adjuvants; COVID-19 vaccines; Subunit vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
- No development reported Coronavirus infections
Most Recent Events
- 20 Nov 2024 Preclinical development is ongoing in COVID-2019 infections
- 28 Oct 2024 No recent reports of development identified for preclinical development in Coronavirus-infections(Prevention) in USA (Parenteral)
- 28 Oct 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Parenteral)